Vepdegestrant for previously treated locally advanced or metastatic ER+/HER2– breast cancer

Vepdegestrant is in development for the treatment of patients with oestrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, who previously received endocrine-based treatment. A locally advanced breast cancer is a stage 3 breast cancer where the cancer has spread from the breast to lymph nodes close to the breast or to the skin of the breast or to the chest wall. Metastatic breast cancer is breast cancer where the cancer has spread to other parts of the body. ER+ breast cancer is a type of breast cancer that expresses the oestrogen hormone receptors (receptors are proteins within or on body cells). HER2 is a protein expressed in some breast cancer cells. HER2- breast cancers have low or no expression of the HER2 protein. Targeted therapies remain an unmet need in the treatment of ER+/HER2- metastatic breast cancer due to the development of resistance to existing hormonal treatment.